Purpose: Single photon emission computed tomography (SPECT) radionuclide pairs having distinct decay rates and different energy maxima enable simultaneous detection of dual gamma signals and real-time assessment of dynamic functional and molecular processes in vivo. Here, we report image acquisition and quantification protocols for a single molecule labeled with two different radionuclides for functional SPECT imaging. Procedures: LS370 and LS734 were prepared using modular solid phase peptide synthesis. Each agent has a caspase-3 cleavable reporting motif, flanked by a tyrosine residue and a chelator at the opposite end of molecule. Cell uptake and efflux were assessed in human MDA-MB-231 breast cancer cells. Biodistribution studies were conducted in tumor naive and orthotopic 4T1 metastatic breast cancer tumor mice. NanoSPECT dual-imaging validation and attenuation correction parameters were developed using phantom vials containing varying radionuclide concentrations. Proof-of-principle SPECT imaging was performed in MMTV-PyMT transgenic mice. Conclusions: Image processing protocols were developed for quantitative signal separation resulting from a caspase-3 responsive dual-radiolabeled SPECT probe. Crosstalk unmixing was obtained for multiradionuclide NanoSPECT imaging. In vitro and in vivo data demonstrated structure-activity relationships for developing functional agents for ratiometric SPECT imaging.
Introduction
T here are many molecular processes involved in cancer progression. The development of molecular therapies and imaging agents targeted to distinct pathological pathways has raised hope for early cancer detection and individualized therapy. An important biomarker of cancer is the diagnostic and prognostic family of proteases [1] . Although they play key roles in normal human physiology, their aberrant expression in cancer results in many undesirable effects such as an increase in tumor proliferation, metastasis, and resistance to therapy. As a result, new targeted therapies have been developed for specifically inhibiting these enzymes in cancer patients. A particularly interesting biochemical event is the migration of some proteases to unusual extracellular or intracellular spaces under pathological conditions, where they exert their cancersupporting roles [2, 3] . In this regard, a combination of quantitative detection of protein expression, localization, and functional status is required for accurate cancer diagnosis and assessment of response to therapy.
Clinically, positron emission tomography (PET) and single photon emission tomography (SPECT) are the molecular imaging techniques of choice because of their high sensitivity and whole-body quantitative imaging capabilities [4] . Elegant methods have been developed to improve in vivo detection sensitivity of predictive enzymes by PET, including the use of [ 18 F]fluorothymidine to report cell proliferation via the activity of thymidine kinase-1 [5] . Despite the unique advantages of these nuclear imaging methods, their applications in molecular imaging have been confined to receptor-targeted imaging of cancer [4] or indirect reporting of the functional status of proteases in vivo by use of radiolabeled inhibitors [6] . Currently, there are no nuclear imaging agents for assessing the functional status of intracellular proteases in vivo.
Unlike PET, where all annihilation photons detected have the same energy (511 keV), which precludes simultaneous discrimination of multiple PET radionuclides from the same tracer, SPECT has multiradionuclide-resolving power. This is because the gamma cameras used in SPECT can acquire projection data simultaneously from two or more radionuclides in separate energy windows with resolution exceeding that of micro-PET [7] . In addition to differences in the emission energies, radionuclides amenable for SPECT imaging have sufficiently long half-lives for timely transportation, and can be produced on site via generators. In (t 1/2 , 2.8 days), make them suitable for incorporation into slow clearing biomolecules such as peptide conjugates, antibodies, and nanoparticles [8] . This compatibility of the biological half-life of the bioconjugates with the radioactive half-life of the elements results in improved signal to background ratios. Conceptually, radiolabeling a protease substrate with two SPECT compatible radioisotopes that emit gamma rays at different energies could provide a new approach for molecular imaging of protease activities via ratiometric SPECT imaging. For this approach to be successful, gamma ray(s) of the chosen nuclides should have minimal overlapping signal in the acceptance energy windows to minimize Bcrosstalk.^For practical reasons, this is not always achievable, leading to the use of radionuclides with significant crosstalk that must be removed in a quantifiable and reproducible manner. Another immediate challenge is to ensure the dual radiolabeling of a single substrate for ratio-SPECT imaging. In the proposed strategy, the selective hydrolysis of an amide bond by the targeted protease will result in the trapping of one radionuclide in cells, while the other radionuclide is effluxed.
Based on these considerations, we have developed a molecular framework for developing and using dual radionuclide-labeled SPECT imaging agents for the molecular imaging of aberrant intracellular or extracellular proteases. Determining therapeutic response can help identify nonresponders at early time points, giving an opportunity to apply an alternative and potentially more effective treatment [9] . In this study, we demonstrated the application of the method by targeting intracellular executioner caspases responsible for induction of apoptosis, and thus are useful for monitoring the early response of tumors to treatment [10, 11] . Two caspase-3 cleavable peptides were radiolabeled with different SPECT radionuclides and evaluated in vitro and in vivo with single or dual SPECT isotopes, 125 I with 99m Tc or 111 In. Acquisition parameters for small animal NanoSPECT imaging were developed for real-time dualisotope SPECT image analysis. Results demonstrate the potential of using multiradionuclide-resolving power of clinically useful SPECT for noninvasively monitoring treatment response.
Materials and Methods
The chelator DOTA-tris(t-Bu ester) was purchased from Macrocyclics (Dallas, TX, USA). Acetic anhydride, N,N-diisopropylethylamine, trifluoroacetic acid (TFA), acetonitrile (ACN), piperidine, anisole, and dimethylformamide (DMF) were purchased from Sigma Aldrich (St. Louis, MO, USA). All the Fmoc amino acids, hydroxybenzotriazole (HOBt), and 2- (1H-benzotriazole-1-yl) 
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Tissue culture protocol is described in the supplemental file. MDA-MB-231 cells used for the uptake and efflux assay were grown on 24-well tissue culture plates until they were 80-90 % confluent with ∼250,000 cells per well. A two-component chemotherapeutic regimen was used that has been shown to initiate apoptosis in breast cancer cells and xenografts [13, 14] . The experimental treatment group of cells was treated with 10 ng/ml of SN-38 (7-ethyl-10-hydroxycamptothecin, Sigma Aldrich) for 24 h. Then, the SN-38 was removed, and the second chemotherapeutic drug, UCN-01 (Sigma Aldrich), was introduced at a concentration of 1 μM in 0. 6 MBq/mmol) were added to treated and control groups. The solutions were added drop-wise into the wells and gently mixed to ensure homogeneous distribution. The final volume per well was 240 μl, and the plates were incubated at 37°C (5 % CO 2 ) for 2 h. After incubation, the supernatant (fraction 1) was collected, and the cells were washed twice with 250 μl of cold serum-free media. The washed cells were incubated again for 1 h in serum-free media at 37°C (5 % CO 2 ), and at 1 h, the supernatant was collected (fraction 2).
Fraction 2 represents the cell efflux, which is the amount of radioactivity released from cells after the 2 h uptake. After collecting the supernatant, Solvable (PerkinElmer) was added to facilitate efficient scraping of the cells. The scraped cells (fraction 3) were collected in microfuge tubes. The radioactivity in each fraction was measured in a well counter (Packard II gamma counter).
Animal Biodistribution Studies
All animal studies were conducted according to guidelines on the humane care and use of laboratory animals under protocols approved by the Animal Studies Committee at Washington University School of Medicine. For tissue biodistribution studies, syngeneic breast tumor models were prepared via bilateral orthotopic implantation of luciferase-transfected 4T1 mouse mammary carcinoma cells (4T1luc, 5×10 5 111 In [t 1/2 = 2.8 days; X-ray, ∼23 keV (82.5 %) and γ-ray, 171 keV (90.6 %), 245 keV (94.1 %)]. The data were acquired in two energy windows, a low-energy window for 125 I (25.2-30.8 keV) and a second encompassing the two high energy peaks of 111 In (140-260 keV) using the NanoSPECT/CT system (Bioscan). As a consequence of this dual-labeling strategy, 125 I measurements were contaminated with 111 In activity due to overlap in the X-ray energy and contamination from down scatter (photons emitted by the higher energy isotope in the energy window of the lower energy isotope). Therefore, a strategy for unmixing of the overlapping gamma ray energy signals was formulated. An unmixing strategy based on the makeup of signals in each collection window (M I and M In ) was developed:
with e I and e In representing the detection efficiencies for 125 I and 111 In in their respective window and e InX the efficiency for detecting the indium X-rays in the 125 In window. C In9I and C I9In are the cross-talk contamination factors from 111 In into the 125 I window and from 125 I into the 111 In window. Under these conditions, e InX cannot be separated from C In9I . C I9In should be small. C In9I is the sum from the down scatter from the 171 and 245 keV gamma rays and X-rays efficiency of 111 In in the 125 I window. Therefore:
The phantoms were made of two ampoules containing a calibrated amount of 111 In (87 μCi) and 125 I (76 μCi). The three-dimensional (3D) regions-of-interest (ROIs) were drawn to encompass the entire ampoules. The dual-isotope SPECT/CT imaging in spontaneous breast cancer model is described in the supplemental text.
Data analysis and statistics are described in the supplemental file.
Results

Synthesis of Caspase-3 Containing Peptide Biomolecules for Imaging Apoptosis
The primary consideration of the molecular design is to ensure that each molecule can be labeled with two energetically different SPECT radionuclides. Thus, the basic structural framework consists of a peptide substrate for the target protease and reactive motifs to selectively incorporate the radionuclides at opposite ends of the peptides. Cleavage of the peptide substrate will alter the biodistribution profiles of the ensuing fragments. By determining the kinetics of each radiative fragment following cleavage, a ratiometric SPECT technique can be developed to report the activity of target enzymes. In this study, we designed molecular imaging probes that are sensitive to the activity of the executioner caspases (caspase-3/7). These caspases, which are upregulated in the early phase of caspase-mediated cell death, recognize and cleave the tetrapeptide motif, DEVD (aspartic acid-glutamic acid-valine-aspartic acid). To illustrate the concept, we designed two molecular imaging agents, LS370 and LS734 (Fig. 1) , containing this motif. Both peptides were prepared by modular solid-phase synthesis. LS370, which contains only nine amino acid peptide sequence, is a simple model of the dual radiolabeled molecular imaging agent for ratiometric SPECT. 
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The data were acquired in two energy windows, one at 30 keV of 125 I and a second encompassing the two high energy peaks of 111 In (171 and 245 keV). The consequence of this dual-labeling strategy is that 125 I measurements are contaminated with 111 In activity due to overlap in the X-ray energy and contamination from down scatter. Based on the unmixing strategy described in BMaterials and Methods,^efficiency and crosscontamination factors were determined by scanning of the calibration phantoms containing known activities of 125 I and 111 In (Fig. 2 ; Tables 1 and 2 ). The 3D ROIs drawn on the entire ampoules and unmixed images were calculated by the arithmetic on the images, not from the ROI data. Figure 3 shows that [
Caspase-3 Mediated Hydrolysis
125 I]LS370 eluted at 19.5 min, and in the presence of caspase-3, the cleaved fragments eluted at 12.5 and 13 min. The presence of two radiolabeled peaks on the radiochromatogram suggests the formation of dimer caused by the expected oxidation of the thiol group to form intermolecular disulfide bond. However, the dimer readily converts back to single molecules under the high reducing conditions such as used to prepare the 99m Tc chelate. Kinetic analysis of caspase-3 activation with [
125 I]LS370 using a radionuclide detector (radio-high-performance liquid chromatography) gave a K M and k cat of 15± 3 μM and 1.02 ± 0.06 M s −1 , respectively. These parameters compared favorably with a standard caspase-3 substrate Ac-DEVD-pNA (K M =11 μM and k cat =2.4 M s −1 ), demonstrating that the radiolabeled peptide was recognized by caspase-3.
Cell-Uptake Assays
The goals of the cell-uptake studies were to (1) assess any changes in the structure-activity relationship resulting from the modular and responsive probe design and (2) evaluate the retention of the iodine containing hydrophobic peptide moiety in treated and untreated cells. Metastatic human breast MDA-MB-231 cells were used to evaluate whether the amino acid sequence modulation would enhance internalization, and how the probe would respond (intracellular) postchemotherapy. In the untreated cells, there was a higher uptake (PG0. (Fig. 4a) . The same trend was observed with the treated cells. The amount of iodinated fraction released by the untreated and treated cells at 3 h (post 2 h incubation and removal of excess activity) was used as a measure of the efflux activity. The results showed that higher amount of activity was released from untreated cells compared to treated cells (Fig. 4b) .
Biodistribution
The structure-activity relationship was evaluated in vivo by performing a tissue biodistribution study in naive (Supplemental Fig. 2 ) and tumor-bearing Balb/c mice (Fig. 5) (Fig. 6) . At early time points, high uptake of an iodinated moiety, resulting from the deiodination of the parent compound, was observed in the thyroid glands. Rapid clearance of 111 In peptide conjugate was indicated by high activity in the kidneys and bladder. Sequential analysis by unmixing of the low-energy window further differentiated the biodistribution of 125 I-and 111 In-labeled compound and its fragments. Some tumorindependent proteolysis of the compound is expected due to minor activity of caspases and proteases in other tissues, particularly the liver and the kidneys. Early clearance of the 125 I-labeled moieties is evident by the relatively high signal from the gastrointestinal tract in the low-energy window (Fig. 6c) . While the iodine containing component was designed to be hydrophobic upon cleavable and separation from the parent compound, the 111 In containing fraction was conceptualized to be hydrophilic following separation from the dual-labeled peptide. Although partial clearance from the liver was observed, the high signal from the kidneys and bladder demonstrated preferential renal to hepatobiliary clearance for the 111 In containing fragments. SUV analysis of the drug-treated and saline-treated tumors showed higher signal in the 111 In channel for the treated (SUV, 2.21) as compared to untreated (SUV, 1.44) tumor. The SUV analysis in the 125 I channel was also quantifiable but confounded by systemic deiodination (treated SUV, 0.19 and saline-treated SUV, 0.21). The ex vivo biodistribution corroborated the in vivo image analysis (Supplemental Fig. 3 ).
Discussion
In the preclinical arena, optical imaging has been used to report a plethora of molecular processes. With its diverse contrast mechanisms, optical imaging is amenable to high throughput screening, real-time feedback, and highly sensitive detection schemes without the use of ionizing radiation or expensive imaging systems. A unique feature of optical imaging is the detection of the expression and the functional status of proteases with high detection sensitivity using activatable reporter probes. Particularly, the commonly used Forster resonance energy transfer (FRET) method for imaging proteases is attractive for studying the functional status of these enzymes because of the near-zero background fluorescence before enzyme activation, resulting in high detection sensitivity and specificity [16] [17] [18] [19] . Despite its enormous potential to unravel the molecular basis of diseases in vivo, the limited tissue penetration depth precludes using optical imaging techniques for noninvasive imaging of deepseated primary and metastatic tumors. Although radionuclide signal cannot be quenched or amplified in the same manner as fluorescence activatable probes, direct readout of protease activity can be achieved by ratiometric SPECT approach. To accomplish this goal, we have designed a dual radionuclide-labeled molecular probe and a SPECT imaging approach for quantitative measurement of protease activity. Our approach is versatile, with potential application in determining the functional status of both intracellular and extracellular proteases. Using a caspase-3 cleavable peptide sequence, we demonstrated that the chemical scaffold on the molecules can be used to alter the cellular internalization and efflux profile of the compounds. For example, the presence of positively charged amino acid residues in LS734 significantly enhanced cell internalization relative to LS370. Further, the ratio of retained activity from the hydrophobic moiety of 125 I-LS734 was higher in the treated cells in vitro versus nontreated cells.
Quantitative accuracy and statistical reconstruction for dual-SPECT isotopes was developed using the available NanoSPECT image reconstruction software. The software design offers select options for three parameters: background correction (in projection data) prior to reconstruction (low, medium, and high), number of iterations (fast, standard, and fine corresponding to 6, 9, and 21 ML-EM iterations), and the pixel size (0.2, 0.3, and 0.4 mm). The standard parameters are low background correction, 9 iterations, and 0.3 mm pixel size. The reconstruction software for the NanoSPECT was evaluated at various scan durations (i.e., counting statistics) with various options within the reconstruction such as the background clean (BC), smooth projection (SP), and smooth volume (SV) using a uniform phantom. We demonstrated that the different levels of background correction (low, medium, and high) did not make any difference in the image. Furthermore, the noise properties for these parameters were identical, as seen on the images using the standard number of iterations (9) and the standard pixel size (0.3 mm; see Supplemental  Fig. 4) . We postulated that the background subtraction was needed to be used in conjunction with the BC option to make a difference. We also observed that the BC option preserved the highest accuracy since the mean ROI values at various scan durations match closely to the reference mean ROI value (i.e., value obtained from the highest counting statistics) compared to the reconstruction with the other options. However, at the lowest counting statistics, the BC option produces the lowest accuracy. This is probably due to bias generated from the background subtraction at low counts. In contrast, the default reconstruction with no additional option produces the highest accuracy at the lowest counting statistics compared to the rest. With regard to the coefficient of variation (STD/mean) of the ROI values (Supplemental Fig. 5 ), the BC option showed the highest variation as expected, whereas the SP option depicts the lowest.
The pharmacokinetic profile in rodents demonstrated the differences in the blood circulation and tissue retention of the bioconjugates. Proof-of-principle animal imaging was performed in the MMTV-PyMT transgenic breast cancer model using the phantom validated customized attenuation and gamma-energy deconvolution SPECT/CT protocols. Cell studies demonstrated differences in the uptake of the dual radiotracer between the treated and nontreated groups. The iodine label was stable in the conditions used for the cell studies (Supplemental Fig. 6 ). However, a key limitation of compound design was the significant 125 I uptake in the thyroid tissue, most likely a function of normal as well as tumor mediated physiologic deiodination caused by the labile carbon-iodine bond [20] . In designing the dual radiolabeled imaging agent, we expected that the intracellular caspase-3 cleavage of the multifunctional molecular agent would result in the trapping of the 125 I-labeled hydrophobic component, while the 111 In-labeled moiety will be cleared. Clearly, deiodination confounded accurate systemic data analysis. In the 111 In channel, the SUV analysis of the drug-and saline-treated tumors showed higher signal for treated (2.21) versus untreated tumors (1.44). In spite of in vivo deiodination, quantitative ROI analysis of various tissues in the 125 I channel was feasible using the described algorithm. The proof-ofprinciple animal study and the phantom studies have laid the foundation for future noninvasive dual radionuclide SPECT studies for imaging intracellular protease activity in response to treatment using biostable imaging probes. We are currently designing imaging agents that better shield the radio-halogen from systemic enzymatic cleavage [21] .
Conclusion
We developed a new approach for imaging protease activity in vivo via a ratiometric SPECT imaging strategy. The synthetic method is modular, which facilitates adaptation of the method to monitor the activities of other diagnostic proteases. Attenuation correction parameters for image reconstruction and quantitative analyses were optimized using phantoms, and successfully implemented for multispectral SPECT image analysis. By modeling the crosstalk between radioisotopes, the SPECT method provides quantitative accuracy for determining the ratios of each radionuclide. This strategy can potentially be adapted to current clinical imaging systems to provide a direct measure of diagnostic molecular biomarkers of early response to therapy.
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